News
Preclinical study explores approved drug for ovarian cancer
Treatment with the iron-binding drug deferiprone elicits a natural killer cell response in a preclinical model of ovarian cancer

An iron-binding drug that is already approved for the treatment of other diseases could provide a novel way to attack ovarian tumours, new research has shown.
Iron is essential for multiple cellular processes, so actively multiplying cancer cells often need larger amounts of it than normal cells. That’s especially true in ovarian cancers.
The preclinical study, led by Weill Cornell Medicine researchers, looked at the iron-binding drug deferiprone and combined the analysis of human ovarian tumours and animal models of the disease. Iron-chelating drugs bind tightly to iron, preventing cells from using it.
“We thought that was a perfect opportunity to try a new approach, because deferiprone has been successfully used for other diseases with abnormal iron accumulation,” said senior author Dr Juan Cubillos-Ruiz, distinguished associate professor for infection and immunology in obstetrics and gynaecology at Weill Cornell Medicine.
To confirm the importance of iron in ovarian cancer, Dr Cubillos-Ruiz’s team first looked at a collection of human tumour samples they have amassed over the past decade and analysed public genomic datasets from ovarian cancer patients.
“We can isolate different components of tumours from ovarian cancer patients, and study their molecular processes,” Cubillos-Ruiz explained.
The scientists found that ovarian cancer cells demonstrate increased expression of iron-related genes, which correlated with poor patient prognosis. The investigators also found that fluid surrounding ovarian tumours contain high iron content that is readily available to cancer cells.
The researchers next looked at animal models of the disease.
“We have advanced mouse models of metastatic ovarian cancer that are immunocompetent, so this allows us to study the immune system response in the disease, which is a crucial component,” Dr Cubillos-Ruiz said.
Previous iron-related studies have used mice with compromised immune systems, precluding the understanding of how different therapies affect immune responses to tumours.
The investigators found that the mice recapitulated the disease features quite well: as ovarian cancer progressed, there was more iron accumulation in the tumour, and the cancer cells selectively over-expressed the iron-related gene signatures.
In the animals, deferiprone treatment worked even better than cisplatin, the current standard for ovarian cancer chemotherapy, and functioned directly inside the cells.
“We demonstrated that deferiprone can chelate iron in ovarian cancer cells, in vivo” said lead author Dr Tito Sandoval, a former postdoctoral fellow in Dr Cubillos-Ruiz’s lab.
“We found that combining cisplatin and deferiprone markedly extended the survival of mice with metastatic ovarian cancer, working synergistically compared with the monotherapies. So, we decided to identify the mechanisms behind this effect.”
The team found that by starving cancer cells of iron, deferiprone triggers a cellular stress response, which prompts the immune system to attack them. Cisplatin affects cancer cell DNA replication, so the two drugs appear to be complementary.
Dr Cubillos-Ruiz is now working with clinical collaborators to design human trials of the new approach.
Though deferiprone is already approved for treating other conditions, he emphasised that the team still needs to determine the best way to use it against ovarian cancer.
“We want to maximise the potential therapeutic effects, so the clinical trial design is critical,” he added.
To receive the Femtech World newsletter, sign up here.
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
pain conditions
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award
















1 Comment